Application of gut microbiome in the diagnosis and treatment of tumor

Abstract

An Jianghong, Qian Shen, Luo Pu, Tan Xiaohua. Application of gut microbiome in the diagnosis and treatment of tumor[J]. Journal of International Oncology, 2021, 48(7): 436-440.

References30

[1]	Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy[J]. Nat Rev Cancer, 2017, 17(5):271-285. DOI: 10.1038/nrc.2017.13. doi:10.1038/nrc.2017.13
[2]	Makki K, Deehan EC, Walter J, et al. The impact of dietary fiber on gut microbiota in host health and disease[J]. Cell Host Microbe, 2018, 23(6):705-715. DOI: 10.1016/j.chom.2018.05.012. doi:10.1016/j.chom.2018.05.012
[3]	Huybrechts I, Zouiouich S, Loobuyck A, et al. The human micro-biome in relation to cancer risk: a systematic review of epidemiologic studies[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(10):1856-1868. DOI: 10.1158/1055-9965.epi-20-0288. doi:10.1158/1055-9965.EPI-20-0288
[4]	Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria[J]. Science, 2020, 368(6494):973-980. DOI: 10.1126/science.aay9189. doi:10.1126/science.aay9189
[5]	Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, et al. Mutational signature in colorectal cancer caused by genotoxic pks⁺E. coli[J]. Nature, 2020, 580(7802):269-273. DOI: 10.1038/s41586-020-2080-8. doi:10.1038/s41586-020-2080-8
[6]	Dejea CM, Fathi P, Craig JM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria[J]. Science, 2018, 359(6375):592-597. DOI: 10.1126/science.aah3648. doi:10.1126/science.aah3648
[7]	Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer[J]. Nat Commun, 2020, 11(1):2168. DOI: 10.1038/s41467-020-16079-x. doi:10.1038/s41467-020-16079-xpmid:32358520
[8]	Yu AI, Zhao L, Eaton KA, et al. Gut microbiota modulate CD8 T cell responses to influence colitis-associated tumorigenesis[J]. Cell Rep, 2020, 31(1):107471. DOI: 10.1016/j.celrep.2020.03.035. doi:10.1016/j.celrep.2020.03.035
[9]	Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371):97-103. DOI: 10.1126/science.aan4236. doi:10.1126/science.aan4236pmid:29097493
[10]	肖俊娟, 毕振旺, 李岩. 肠道微生态与肿瘤免疫调节的相关研究[J]. 国际肿瘤学杂志, 2017, 44(1):34-37. DOI: 10.3760/cma.j.issn.1673-422x.2017.01.009.
[11]	Riquelme E, Zhang Y, Zhang L, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes[J]. Cell, 2019, 178(4):795-806, e12. DOI: 10.1016/j.cell.2019.07.008. doi:S0092-8674(19)30773-1pmid:31398337
[12]	Pushalkar S, Hundeyin M, Daley D, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression[J]. Cancer Discov, 2018, 8(4):403-416. DOI: 10.1158/2159-8290.cd-17-1134. doi:10.1158/2159-8290.CD-17-1134pmid:29567829
[13]	Ferrie S, Webster A, Wu B, et al. Gastrointestinal surgery and the gut microbiome: a systematic literature review[J]. Eur J Clin Nutr, 2020, In press. DOI: 10.1038/s41430-020-0681-9.
[14]	van Praagh JB, de Goffau MC, Bakker IS, et al. Mucus microbiome of anastomotic tissue during surgery has predictive value for colorectal anastomotic leakage[J]. Ann Surg, 2019, 269(5):911-916. DOI: 10.1097/sla.0000000000002651. doi:10.1097/SLA.0000000000002651
[15]	Gaines S, van Praagh JB, Williamson AJ, et al. Western diet promotes intestinal colonization by collagenolytic microbes and promotes tumor formation after colorectal surgery[J]. Gastroenterology, 2020, 158(4):958-970, e2. DOI: 10.1053/j.gastro.2019.10.020. doi:S0016-5085(19)41471-6pmid:31655031
[16]	Darbandi A, Mirshekar M, Shariati A, et al. The effects of probio-tics on reducing the colorectal cancer surgery complications: a perio-dic review during 2007—2017[J]. Clin Nutr, 2020, 39(8):2358-2367. DOI: 10.1016/j.clnu.2019.11.008. doi:S0261-5614(19)33135-8pmid:31831184
[17]	Panebianco C, Andriulli A, Pazienza V. Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies[J]. Microbiome, 2018, 6(1):92. DOI: 10.1186/s40168-018-0483-7. doi:10.1186/s40168-018-0483-7pmid:29789015
[18]	Loman BR, Jordan KR, Haynes B, et al. Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice[J]. Sci Rep, 2019, 9(1):16490. DOI: 10.1038/s41598-019-52893-0. doi:10.1038/s41598-019-52893-0pmid:31712703
[19]	Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy[J]. Cell, 2017, 170(3):548-563, e16. DOI: 10.1016/j.cell.2017.07.008. doi:10.1016/j.cell.2017.07.008
[20]	Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction[J]. Gut, 2018, 67(1):97-107. DOI: 10.1136/gutjnl-2017-313789. doi:10.1136/gutjnl-2017-313789pmid:28438965
[21]	Cui M, Xiao H, Li Y, et al. Faecal microbiota transplantation protects against radiation-induced toxicity[J]. EMBO Mol Med, 2017, 9(4):448-461. DOI: 10.15252/emmm.201606932. doi:10.15252/emmm.201606932
[22]	Guo H, Chou WC, Lai Y, et al. Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites[J]. Science, 2020, 370(6516):eaay9097. DOI: 10.1126/science.aay9097. doi:10.1126/science.aay9097
[23]	Liu MM, Li ST, Shu Y, et al. Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials[J]. PLoS One, 2017, 12(6):e0178870. DOI: 10.1371/journal.pone.0178870. doi:10.1371/journal.pone.0178870
[24]	Chalabi M, Cardona A, Nagarkar DR, et al. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials[J]. Ann Oncol, 2020, 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. doi:S0923-7534(20)35927-5pmid:32115349
[25]	Wang Y, Wiesnoski DH, Helmink BA, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis[J]. Nat Med, 2018, 24(12):1804-1808. DOI: 10.1038/s41591-018-0238-9. doi:10.1038/s41591-018-0238-9
[26]	Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab[J]. Ann Oncol, 2017, 28(6):1368-1379. DOI: 10.1093/annonc/mdx108. doi:10.1093/annonc/mdx108pmid:28368458
[27]	Zheng DW, Chen Y, Li ZH, et al. Optically-controlled bacterial metabolite for cancer therapy[J]. Nat Commun, 2018, 9(1):1680. DOI: 10.1038/s41467-018-03233-9. doi:10.1038/s41467-018-03233-9
[28]	Mager LF, Burkhard R, Pett N, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy[J]. Science, 2020, 369(6510):1481-1489. DOI: 10.1126/science.abc3421. doi:10.1126/science.abc3421
[29]	Gregory AC, Zablocki O, Zayed AA, et al. The Gut Virome Database reveals age-dependent patterns of virome diversity in the human gut[J]. Cell Host Microbe, 2020, 28(5):724-740, e8. DOI: 10.1016/j.chom.2020.08.003. doi:10.1016/j.chom.2020.08.003
[30]	Lim B, Zimmermann M, Barry NA, et al. Engineered regulatory systems modulate gene expression of human commensals in the gut[J]. Cell, 2017, 169(3):547-558, e15. DOI: 10.1016/j.cell.2017.03.045. doi:10.1016/j.cell.2017.03.045

Application of gut microbiome in the diagnosis and treatment of tumor

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References30

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[6]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong.Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(4): 210-216.
[7]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[8]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[9]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150.
[10]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[11]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[12]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[13]	Cui Tenglu, Lyu lu, Sun Pengfei.Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(9): 548-552.
[14]	Guo Ciliang, Jiang Chunping, Wu Junhua.Gut microbiome and tumor immunotherapy[J]. Journal of International Oncology, 2023, 50(7): 432-436.
[15]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.